Medigene AG: Medigene announces participation at six national and international conferences

Planegg (pta007/28.03.2017/07:30 UTC+2) Medigene AG (FWB: MDG1, Prime Standard, TecDAX) today announced its participation at six upcoming scientific and investor conferences:

* Metzler MicroCap Day
Date: March 29 - 30, 2017
Location: Frankfurt/Main, Germany

* American Association for Cancer Research - AACR Annual Meeting
Date: April 1 - 5, 2017
Location: Washington DC, USA
Dr. Manon Weis, scientist, gives an oral presentation on April 4th at 03.05 PM
on the topic: "Isolation and characterization of a PRAME-specific TCR with high avidity, potent antitumor efficacy and a favorable preclinical safety profile". An abstract is available under: (http://www.abstractsonline.com/pp8/#!/4292/presentation/5970)

Furthermore, our cooperation partner from the Oslo University Hospital will present a poster on April 4th during 08.00 AM to 12.00 PM on the topic: "WT1 and PRAME mRNA transfected TLR 7/8-polarized fast DC vaccines in AML patients mount specific immune responses and impact progression free survival". An abstract is available under: (http://www.abstractsonline.com/pp8/#!/4292/presentation/5996)

* 16th Annual Needham Healthcare Conference
Date: April 4 - 5, 2017
Location: New York, USA
Medigenes CFO, Dr. Thomas Taapken, will hold a company presentation on April 4th at 05.00 PM.

* 24th BioCentury Future Leaders in the Biotech Industry
Date: April 7, 2017
Location: New York, USA
Medigenes CFO, Dr. Thomas Taapken, will hold a company presentation at 10.30 AM.

* Molecular Diagnostics Europe
Date: April 10 - 13, 2017
Location: Lisbon, Portugal

* European Neoantigen Summit 2017
Date: April 24 -26, 2017
Location: Amsterdam, Netherlands
Prof. Dolores Schendel, Medigenes CEO / CSO, gives a presentation on April 26th at 01.45 PM on the topic: "Rapid High-Throughput Technologies Allow Functional Identification of Neoantigens for Vaccines and TCR-Based Immunotherapies".

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in clinical and pre-clinical development.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)

Emitter:	Medigene AG Lochhammer Straße 11 82152 Planegg Germany
Contact Person:	Julia Hofmann, Head of Public & Investor Relations
Phone:	+49 89 200033-3301
E-Mail:	investor@medigene.com
Website:	www.medigene.de
ISIN(s):	DE000A1X3W00 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate